Form 8-K - Current report
March 08 2024 - 4:00PM
Edgar (US Regulatory)
false
0001859007
0001859007
2024-03-06
2024-03-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 6, 2024
ZYVERSA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41184 |
|
86-2685744 |
(State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2200
N. Commerce Parkway, Suite 208
Weston,
Florida |
|
33326 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(754)
231-1688
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbols |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
ZVSA |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
March 6, 2024, ZyVersa Therapeutics, Inc. (the “Company”) received a Letter of Reprimand (the “Letter”)
from the staff (the “Staff”) of the Nasdaq Stock Market (the “Nasdaq”) in accordance with Nasdaq’s
Listing Rule 5810(c)(4). The Staff has determined that the Company’s July 2023 best-efforts public offering of its common
stock (“Common Stock”) and warrants to purchase shares of the Common Stock (the “July 2023 Offering”)
did not qualify as a “Public Offering” as defined in Nasdaq’s Listing Rule IM-5635-3. Accordingly, because the July
2023 Offering was carried out at a price less than the “Minimum Price,” as defined in Nasdaq’s Listing Rule IM-5635(d)
and the July 2023 Offering included Common Stock and warrants to purchase Common Stock in an amount greater than 20% of the then
outstanding shares of Common Stock, the Company was required to obtain stockholder approval prior to the July 2023 Offering, pursuant
to Nasdaq’s Listing Rule 5635(d). The Staff also determined that the Company’s repricing of certain warrants to purchase
shares of Common Stock in connection with the July 2023 Offering were aggregated with the securities sold in the July 2023 Offering to
increase the deemed discount of the July 2023 Offering below the “Minimum Price.” Further, the Staff determined that the
Company’s subsequent repricing of warrants to purchase shares of Common Stock in September 2023 aggregated with the securities
issued in the July 2023 Offering to further discount the offering price. The Company believed the July 2023 Offering qualified as a “Public
Offering,” as defined in Nasdaq’s Listing Rule IM-5635-3.
The
Staff determined that it is appropriate to close the matters described above and issue the Letter. In coming to its conclusion, the Staff
noted that the Company’s failure to adhere to Nasdaq’s continued listing standards did not appear to be the result of deliberate
intent to avoid compliance. The Staff also noted that the Company believed the July 2023 Offering was in the Company’s best interests
and the Company had not demonstrated a prior pattern of non-compliance with Nasdaq stockholder approval rules. Following the issuance
of the Letter no further action needs to be taken by the Company.
Item
8.01 Other Events.
As
previously disclosed in the Company’s Current Report on Form 8-K filed June 12, 2023, on June 9, 2023, the received a letter from
the Staff indicating that, based upon the closing bid price of the Common Stock for the prior 30 consecutive business days, the Company
was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Global
Market, as set forth in Nasdaq’s Listing Rule 5550(a)(2) (the “Bid Price Deficiency”). The Company presented a plan of compliance to the Nasdaq Hearings Panel, which provided
the Company until May 3, 2024, to cure the Bid Price Deficiency.
On
March 8, 2024, the Company filed a preliminary proxy statement with the Securities and Exchange Commission (the “SEC”)
regarding a special stockholders’ meeting to be held on April 17, 2024 (the “Special Meeting”), to submit a
proposal to the Company’s stockholders to approve a reverse stock split (the “Reverse Stock Split”) of the Common
Stock at a ratio between 1-for-2 to 1-for-50, which the Company believes will lower the amount of shares of Common Stock outstanding
and cause an increase in the price per share of Common Stock to cure the Bid Price Deficiency. However, the
Company hopes that implementing the Reverse Stock Split will not be necessary given what the Company believes is increased investor
confidence in the value of the Company from, among other things, the data published in the March, 2024 issue of the Journal of Pharmacology
and Experimental Therapeutics demonstrating that NLRP3 inhibitors have potential to treat obesity with weight loss efficacy similar to
the current gold-standard, GLP-1 receptor agonists, with added cardiovascular benefits. This news became viral among financial reporters,
and was associated with high volume trading and increased stock prices for companies developing inflammasome inhibitors, including that
of the Company, who is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit multiple types of inflammasomes, including
NLRP3, and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation associated with obesity and
numerous other conditions. The Company believes this, and the Company’s expected initiation within the next few weeks of a phase
2a clinical trial with Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease, has potential to increase
the trading price of the Common Stock to above $1.00, causing the Staff to determine that the Bid Price Deficiency is cured. The board
of directors of the Company (the “Board”) retains the right to abandon the Reverse Stock Split in its sole discretion, including
upon the Staff determining that the Company has cured its Bid Price Deficiency as a result of an increase in the trading price of the
Common Stock.
If,
in any event, including if the Bid Price Deficiency remains outstanding at time of the Special Meeting, the Board determines to implement
the Reverse Stock Split, there is no assurance that it will result in an increased per share price, or achieve its other intended effects.
Forward
Looking Statements
This
Current Report on Form 8-K (the “Current Report”) contains forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding the Company’s
future expectations, plans and prospects, including, without limitation, statements regarding the Company’s ability to effect the
Reverse Stock Split and an increase in the trading price of the Common Stock as a result of the Reverse Stock Split, as well as other
statements that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.
The
express or implied forward-looking statements included in this Current Report are only predictions and are subject to a number of risks,
uncertainties and assumptions, including, without limitation risks concerning the Company’s ability to effect the Reverse Stock
Split, the impact of the Reverse Stock Split on the Common Stock or business, the Staff’s determination that the Bid Price Deficiency
is cured, and risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, its Quarterly Reports
on Form 10-Q and other filings made with the SEC. Although the Company’s forward-looking statements reflect the good faith judgment
of its management, these statements are based only on information and factors currently known by the Company. As a result, you are cautioned
not to rely on these forward-looking statements. Any forward-looking statement made in this Current Report speaks only as of the date
on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result
of new information, future developments or otherwise.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ZYVERSA
THERAPEUTICS, INC. |
|
|
|
March
8, 2024 |
By: |
/s/
Stephen Glover |
|
Name: |
Stephen
Glover |
|
Title: |
Chief
Executive Officer |
v3.24.0.1
Cover
|
Mar. 06, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Mar. 06, 2024
|
Entity File Number |
001-41184
|
Entity Registrant Name |
ZYVERSA
THERAPEUTICS, INC.
|
Entity Central Index Key |
0001859007
|
Entity Tax Identification Number |
86-2685744
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2200
N. Commerce Parkway
|
Entity Address, Address Line Two |
Suite 208
|
Entity Address, City or Town |
Weston
|
Entity Address, State or Province |
FL
|
Entity Address, Postal Zip Code |
33326
|
City Area Code |
(754)
|
Local Phone Number |
231-1688
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
ZVSA
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2024 to May 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2023 to May 2024